Point and Figure Charting Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Point and Figure Charting

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: James Strauss who wrote (20568)	5/28/1999 2:36:00 PM
From: Logain Ablar	Read Replies (2) of 34811

James: I can only comment on what I've seen with Lilly and Ligand. Its more financially prudent for a large pharma to "invest" in a biotech when the biotech needs the money. Lilly gets great upside while minimizing its downside. If they purchased the company they'd end up paying for more than just one product and have to make the decision to continue investing or just focus on the one they're interested in. We all dream of the home run but a Lilly is more risk adverse. You can see this with many of the strategic investments. (PFE just did one with Neuopegen for $20m a few weeks ago). Don't forget for every drug that makes it through the FDA trial there are 100 that don't make from PI to PIII. Maybe the # will start to narrow as the biotech industry matures but thats a lot of risk. Right now I like Sepacor and IMNX. IMNX is one of Judy's. Tim

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next